Cover Image
市場調查報告書

非黑色素瘤皮膚癌治療的全球市場

Global Non-melanoma Skin Cancer Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 305015
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
非黑色素瘤皮膚癌治療的全球市場 Global Non-melanoma Skin Cancer Market 2014-2018
出版日期: 2014年05月23日 內容資訊: 英文 119 Pages
簡介

非黑色素瘤皮膚癌是全世界最常見的癌症之一。非黑色素瘤皮膚癌有2種。一種是BCC基底細胞發生,另一個是SCC在臉和耳朵、頭、嘴唇及手背等發病。非黑色素瘤皮膚癌,是由於過度暴露於紫外線而發病。治療方法有外科手術、雷射療法、冷卻療法、藥膏、放射線治療、化療、光線動態療法(PDT)。非黑色素瘤皮膚癌治療的全球市場預計從2013年到2018年期間,以27.93%的年複合成長率(CAGR)持續擴大。

本報告提供非黑色素瘤皮膚癌治療的全球市場相關研究,及來自產業多數專家的資料、資訊之詳細市場分析、各市場領域的各種收益額到市場規模。

第1章 摘要整理

第2章 簡稱表

第3章 本報告的填補範圍

  • 市場概要
  • 提供內容

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 序論

第6章 市場情形

  • 市場概要
  • 市場規模及未來預測
  • 非黑色素瘤皮膚癌治療藥的全球市場
    • 市場規模及未來預測
  • 日光角化症治療藥的全球市場
    • 市場概要
    • 市場規模及未來預測
  • BCC、SCC,及日光角化症治療藥的暢銷產品
  • 波特的五力分析

第7章 各類型市場分析

  • 各類型非黑色素瘤皮膚癌治療藥全球市場
    • BCC
    • SCC
  • BCC治療藥全球市場
    • 市場規模及未來預測
  • SCC治療藥全球市場
    • 市場規模及未來預測

第8章 開發平台分析

第9章 地區市場分析

  • 非黑色素瘤皮膚癌治療藥全球市場的各地區分類

第10章 購買標準

第11章 市場成長推動要素

第12章 市場成長推動要素與其造成的影響

第13章 市場課題

第14章 市場成長促進要素和市場課題帶來的影響

第15章 市場趨勢

第16章 市場趨勢與其造成的影響

第17章 供應商情形

  • 市場佔有率分析
  • 日光角化症治療藥全球市場
  • 其他重要供應商

第18章 非侵入式治療市場

  • 非黑色素瘤皮膚癌的放射線治療全球市場
    • 市場規模及未來預測
  • 非黑色素瘤皮膚癌的冷卻療法全球市場
    • 市場規模及未來預測
  • 非黑色素瘤皮膚癌的光線動態療法(PDT)全球市場
    • 市場規模及未來預測
  • 非黑色素瘤皮膚癌的雷射療法全球市場
    • 市場規模及未來預測
  • 廠商市場佔有率
    • 非黑色素瘤皮膚癌的放射線治療設備全球市場
    • 非黑色素瘤皮膚癌的冷卻療法設備全球市場
    • 非黑色素瘤皮膚癌的光線動態療法(PDT)設備全球市場
    • 非黑色素瘤皮膚癌的雷射療法設備全球市場

第19章 主要供應商分析

  • Elekta AB
  • F. Hoffmann-La Roche Ltd.
  • iCAD Inc.
  • Meda AB
  • Valeant Pharmaceuticals International Inc.
  • Varian Medical Systems Inc.

第20章 相關報告

目錄
Product Code: IRTNTR3605

About Non-melanoma Skin Cancer

Non-melanoma skin cancer is one of the most common types of cancer in the world. It develops in the upper layers of the skin, but not in melanocytes. There are two types of non-melanoma skin cancer: BCC, which starts in the basal cells, and SCC, which starts in the squamous cells. BCC usually develops in the areas such as the head and neck, whereas SCC starts in the face, ears, neck, lips, and backs of the hands. These can also grow in wounds or chronic skin sores. Non-melanoma skin cancer is caused by unprotected and excessive exposure to UV radiation. It affects men more than women. It can be cured effectively if it is detected early. Treatment for non-melanoma skin cancer includes surgery, laser therapy, cryotherapy, creams, radiotherapy, chemotherapy, and PDT.

TechNavio's analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments:

Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis

Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy

TechNavio's report, the Global Non-melanoma Skin Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and, the EMEA and the APAC region; and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Elekta AB
  • F. Hoffmann-la Roche Ltd.
  • iCAD Inc.
  • Meda AB
  • Valeant Pharmaceuticals Inc.
  • Varian Medical Systems Inc.

Other Prominent Vendors

  • Aqua Pharmaceuticals LLC
  • Almirall SA
  • Biofrontera AG
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Cannabis Science Inc.
  • Cellceutix Corp.
  • Eli Lilly and Co.
  • Galderma SA
  • GENEXTRA SpA
  • IRX Therapeutics Inc.
  • LEO Pharma A/S
  • Merck & Co. Inc.
  • Moberg Pharma AB
  • Mylan Pharmaceutical Inc.
  • Novartis International AG
  • Oncothyreon Inc.
  • Sun Pharma Industries Ltd.

Market Driver

  • Increasing Incidence of Non-melanoma Skin Cancer

For a full, detailed list, view our report.

Market Challenge

  • Availability of Alternative Treatments

For a full, detailed list, view our report.

Market Trend

  • Emergence of Combination Therapies

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Global Non-melanoma Skin Cancer Drugs Market
    • 06.3.1. Market Size and Forecast
  • 06.4. Global Actinic Keratosis Drugs Market
    • 06.4.1. Market Overview
    • 06.4.2. Market Size and Forecast
  • 06.5. Top Selling Drugs for the Treatment of BCC, SCC, and Actinic Keratosis
  • 06.6. Five Forces Analysis

07. Market Segmentation by Type

  • 07.1. Global Non-melanoma Skin Cancer Drugs Market by Type
    • 07.1.1. BCC
    • 07.1.2. SCC
  • 07.2. Global BCC Drugs Market
    • 07.2.1. Market Size and Forecast
  • 07.3. Global SCC Drugs Market
    • 07.3.1. Market Size and Forecast

08. Pipeline Analysis

09. Geographical Segmentation

  • 09.1. Global Non-melanoma Skin Cancer Market by Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Market Share Analysis 2013
  • 17.2. Global Actinic Keratosis Drugs Market
  • 17.3. Other Prominent Vendors

18. Non-invasive Treatment Market

  • 18.1. Global Non-melanoma Skin Cancer Radiotherapy Market
    • 18.1.1. Market Size and Forecast
  • 18.2. Global Non-melanoma Skin Cancer Cryotherapy Market
    • 18.2.1. Market Size and Forecast
  • 18.3. Global Non-melanoma Skin Cancer PDT Market
    • 18.3.1. Market Size and Forecast
  • 18.4. Global Non-melanoma Skin Cancer Laser Therapy Market
    • 18.4.1. Market Size and Forecast
  • 18.5. Vendor Share
    • 18.5.1. Global Non-melanoma Skin Cancer Radiotherapy Equipment Market
    • 18.5.2. Global Non-melanoma Skin Cancer Cryotherapy Equipment Market
    • 18.5.3. Global Non-melanoma Skin Cancer PDT Equipment Market
    • 18.5.4. Global Non-melanoma Skin Cancer Laser Equipment Market

19. Key Vendor Analysis

  • 19.1. Elekta AB
    • 19.1.1. Key Facts
    • 19.1.2. Business Description
    • 19.1.3. Product Categorization
    • 19.1.4. Revenue by Product Offerings
    • 19.1.5. Revenue Comparison by Geographical Segmentation 2012 and 2013
    • 19.1.6. Revenue Comparison by Geographical Segmentation
    • 19.1.7. Business Strategy
    • 19.1.8. Key Developments
    • 19.1.9. SWOT Analysis
    • 19.1.10. Strengths
    • 19.1.11. Weaknesses
    • 19.1.12. Opportunities
    • 19.1.13. Threats
  • 19.2. F. Hoffmann-La Roche Ltd.
    • 19.2.1. Key Facts
    • 19.2.2. Business Description
    • 19.2.3. Business Segmentation
    • 19.2.4. Revenue by Business Segmentation
    • 19.2.5. Geographical Sales Segmentation by Business Segments
    • 19.2.6. Business Strategy
    • 19.2.7. Key Information
    • 19.2.8. SWOT Analysis
    • 19.2.9. Strengths
    • 19.2.10. Weaknesses
    • 19.2.11. Opportunities
    • 19.2.12. Threats
  • 19.3. iCAD Inc.
    • 19.3.1. Key Facts
    • 19.3.2. Business Description
    • 19.3.3. Business Segmentation
    • 19.3.4. Revenue by Business Segmentation
    • 19.3.5. Revenue Comparison by Business Segmentation 2012 and 2013
    • 19.3.6. Revenue by Geographical Segmentation
    • 19.3.7. Business Strategy
    • 19.3.8. Key Developments
    • 19.3.9. SWOT Analysis
    • 19.3.10. Strengths
    • 19.3.11. Weaknesses
    • 19.3.12. Opportunities
    • 19.3.13. Threats
  • 19.4. Meda AB
    • 19.4.1. Key Facts
    • 19.4.2. Business Description
    • 19.4.3. Product Segmentation
    • 19.4.4. Revenue by Product Segmentation
    • 19.4.5. Revenue Comparison by Product Segmentation 2012 and 2013
    • 19.4.6. Revenue by Geographical Segmentation
    • 19.4.7. Business Strategy
    • 19.4.8. Key Developments
    • 19.4.9. SWOT Analysis
    • 19.4.10. Strengths
    • 19.4.11. Weaknesses
    • 19.4.12. Opportunities
    • 19.4.13. Threats
  • 19.5. Valeant Pharmaceuticals International Inc.
    • 19.5.1. Key Facts
    • 19.5.2. Business Description
    • 19.5.3. Business Segmentation
    • 19.5.4. Revenue Comparison by Business Segmentation 2011-2013
    • 19.5.5. Revenue by Geographical Segmentation
    • 19.5.6. Business Strategy
    • 19.5.7. Key Developments
    • 19.5.8. SWOT Analysis
    • 19.5.9. Strengths
    • 19.5.10. Weaknesses
    • 19.5.11. Opportunities
    • 19.5.12. Threats
  • 19.6. Varian Medical Systems Inc.
    • 19.6.1. Key Facts
    • 19.6.2. Business Description
    • 19.6.3. Business Segmentation
    • 19.6.4. Revenue by Business Segmentation
    • 19.6.5. Revenue Comparison by Business Segmentation 2013 and 2012
    • 19.6.6. Revenue by Geographical Segmentation
    • 19.6.7. Business Strategy
    • 19.6.8. Key Developments
    • 19.6.9. SWOT Analysis
    • 19.6.10. Strengths
    • 19.6.11. Weaknesses
    • 19.6.12. Opportunities
    • 19.6.13. Threats

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Non-melanoma Skin Cancer Market Segmentation by Type
  • Exhibit 3: Global Non-melanoma Skin Cancer Market 2013-2020 (US$ million)
  • Exhibit 4: Global Non-melanoma Skin Cancer Drugs Market 2013-2020 (US$ million)
  • Exhibit 5: Global Actinic Keratosis Drugs Market 2013-2020 (US$ million)
  • Exhibit 6: Global Non-melanoma Skin Cancer Drugs Market Segmentation by Type
  • Exhibit 7: Global Non-melanoma Skin Cancer Drugs Market Segmentation by Type 2013
  • Exhibit 8: Global BCC Drugs Market 2013-2020 (US$ million)
  • Exhibit 9: Global SCC Drugs Market 2013-2020 (US$ million)
  • Exhibit 10: Global Non-melanoma Skin Cancer Market by Geographical Segmentation 2013
  • Exhibit 11: Global Actinic Keratosis Drugs Market by Vendor Segmentation 2013
  • Exhibit 12: Global Non-melanoma Skin Cancer Radiotherapy Market 2013-2020 (US$ million)
  • Exhibit 13: Global Non-melanoma Skin Cancer Cryotherapy Market 2013-2020 (US$ million)
  • Exhibit 14: Global Non-melanoma Skin Cancer PDT Market 2013-2020 (US$ million)
  • Exhibit 15: Global Non-melanoma Skin Cancer Laser Therapy Market 2013-2020 (US$ million)
  • Exhibit 16: Global Non-melanoma Skin Cancer Radiotherapy Equipment Market by Vendor Segmentation 2013
  • Exhibit 17: Global Non-melanoma Skin Cancer Cryotherapy Equipment Market by Vendor Segmentation 2013
  • Exhibit 18: Global Non-melanoma Skin Cancer PDT Equipment Market by Vendor Segmentation 2013 51
  • Exhibit 19: Vendors in Global Non-melanoma Skin Cancer Laser Equipment Market
  • Exhibit 20: Elekta AB: Product Categorization
  • Exhibit 21: Elekta AB: Revenue by Product Offerings 2013
  • Exhibit 22: Elekta AB: Revenue Comparison by Geographical Segmentation 2012 and 2013 (US$ million)
  • Exhibit 23: Elekta AB: Revenue Comparison by Geographical Segmentation 2013
  • Exhibit 24: F. Hoffmann-la Roche Ltd.: Business Segmentation 2013
  • Exhibit 25: F. Hoffmann-la Roche Ltd.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 26: F. Hoffmann-la Roche Ltd.: Revenue of Pharmaceuticals Division by Geographical Segmentation 2013
  • Exhibit 27: F. Hoffmann-la Roche Ltd.: Revenue of Diagnostics Division by Geographical Segmentation 2013
  • Exhibit 28: iCAD Inc.: Business Segmentation
  • Exhibit 29: iCAD Inc.: Revenue by Business Segmentation 2013
  • Exhibit 30: iCAD Inc.: Revenue Comparison by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 31: iCAD Inc.: Revenue by Geographical Segmentation 2013
  • Exhibit 32: Meda AB: Product Segmentation
  • Exhibit 33: Meda AB: Revenue by Product Segmentation 2013
  • Exhibit 34: Meda AB: Revenue Comparison by Product Segmentation 2012 and 2013 (US$ billion)
  • Exhibit 35: Meda AB: Revenue by Geographical Segmentation 2013
  • Exhibit 36: Valeant Pharmaceuticals International Inc.: Business Segmentation 2013
  • Exhibit 37: Valeant Pharmaceuticals International Inc.: Revenue Comparison by Business Segmentation 2011-2013 (US$ million)
  • Exhibit 38: Valeant Pharmaceuticals International Inc.: Revenue by Geographical Segmentation 2013
  • Exhibit 39: Varian Medical Systems Inc.: Business Segmentation
  • Exhibit 40: Varian Medical Systems Inc.: Revenue by Business Segmentation 2013
  • Exhibit 41: Varian Medical Systems Inc.: Revenue Comparison by Business Segmentation (US$ million)
  • Exhibit 42: Varian Medical Systems Inc.: Revenue Segmentation by Geographical Segmentation 2013
Back to Top